Scil Proteins establishes business development organisation in California

To be headed by Garry Merry

Scil Proteins, a German biotech specialist in the research, development and production of recombinant proteins, has established a business development organisation in California in response to increasing demand for the company’s protein production services in North America. The organisation, to be led by Garry Merry, will provide local business support for the company’s US and Canadian CMO customers.

Merry has a wealth of experience supporting the business development efforts of several small protein engineering, biopharmaceutical and drug discovery companies in North America, including Sloning Biotechnologies, Isogenica and TerraSep. He has also held senior executive positions at life science companies including Waters, Applied Biosystems and Qiagen.

‘A local presence to interface directly with our customers, collaborators and partners in North America is vital to ensure our continued success and the expansion of our business on a global basis,’ said Frank Ubags, chief operating officer of Scil Proteins. ‘With his background in protein engineering and separations, Garry is ideally positioned to help us achieve our growth objectives.’

Scil Proteins’ Affilin drug discovery platform, which is available for out-licensing to biotechnology and pharmaceutical companies, will continue to be supported out of the company’s headquarters in Halle, Germany. The corporate headquarters will also remain responsible for all other activities related to the company’s CMO business outside the US and Canada.

You may also like

Research & Development

ITM and Scil Proteins agree targeted radio conjugates partnership

German firms will develop targeted radio conjugates for imaging and therapy purposes, in a variety of indications
Ingredients

Scil Proteins receives EMA approval for commercial production of Reteplase

The recombinant protein will be produced in Halle, Germany
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Drug Delivery

Optimised fittings for microfluidic systems

Miniature flat-bottom ports combine convenience and performance for precise fluid control
Subscribe now